NetworkNewsBreaks – ARCA Biopharma, Inc. (NASDAQ: ABIO) Posts Q1 Financial Results, Pipeline Progress; Presenting Clinical Trial Results at Heart Failure 2018 World Congress
ARCA biopharma (NASDAQ: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, recently reported financial results for the quarter ended March 31, 2018, as well as an update regarding its lead product candidate, Gencaro™. Among other highlights, the company reported ending the quarter with cash, cash equivalents and marketable securities of $12.1 million, compared to $11.8 million as of December 31, 2017. The company has scheduled an end-of-phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) for the last week of June to review data from the GENETIC-AF clinical trial and…







